Course:
CME Credits: 0.50
Released: 2025-05-08
Treatment of CLL/small lymphocytic lymphoma (SLL) often begins with a period of observation. Therapy depends on signs and symptoms, as well as the patient’s quality of life. First- and second-line treatment selection depends on multiple factors; however, many oncology and/or hematology clinicians are challenged to determine when to initiate treatment or when to conduct cytogenetic and molecular testing. Patient management is complex, and will be highlighted and discussed in this activity for oncology and hematology clinicians who care for patients with CLL/SLL.
Upon completion of this activity, participants should be able to:
View Full Course